Abstract
A tantalum AVN implant was used in sixteen patients with advanced AVN (Grade 3/4). No reports have been published of use of this implant in advanced disease. Outcomes included radiological, SF36, Harris hip score and secondary surgeries. HHS improved from fifty-two to seventy. SF36 scores approached controls. At over one year average follow-up five patients are revised to THA, however, all hips except one have at least minor pain. Revisions occurred in older patients or those with 100% head involvement. In younger patients, with up to 50% head involvement, this technique seems to be a viable option for advanced AVN. Evaluation of tantalum AVN implants in patients with advanced AVN. In younger patients, with up to 50% hip head involvement, this technique seems to be a viable option for advanced AVN. Revisions in general are in older patients or those with 100% head involvement.
Most treatment options have had poor outcomes with advanced AVN. Surgeons generally perform THA or core decompression in these cases. Market pressure for a non-vascularized option to fill the channel after decompression has resulted in new implants. A tantalum device has been designed to fill the post-core decompression channel to allow subchondral support. This is a minimally invasive procedure with theoretically low morbidity. The average orthopedic surgeon would have no difficulty in the use of this implant.
HHS improved from fifty-two to seventy. SF36 scores were below age-matched controls. At over one-year average follow-up five patients are revised to THA, however, all hips except one have at least minor pain. Revisions in general are in older patients or those with 100% involvement. In younger patients, with up to 50% head involvement, this technique seems to be a viable option.
This device was used in a prospective cohort of sixteen patients with advanced AVN (Grade 3/4) with femoral head fracture/collapse. Operative technique including reduction of the fracture allows for improved results. Outcomes included radiological parameters (advancing disease, placement, ingrowth), SF36, Harris hip score and secondary surgeries.
Correspondence should be addressed to Cynthia Vezina, Communications Manager, COA, 4150-360 Ste. Catherine St. West, Westmount, QC H3Z 2Y5, Canada
